AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24188056 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall healthcare resource utilization
Number of subjects: 3508
Study 24188226 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH)
Number of subjects: 0
Study 24188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair of aortic aneurysm with patent collateral beds
Number of subjects: 1251
Study 24188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair of aortic aneurysm with occluded collateral beds
Number of subjects: 1251
Study 24188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with immediate presentation of SCI
Number of subjects: 1251
Study 24188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with occlusion of at least one collateral bed
Number of subjects: 1251
Study 24188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with permanent SCI
Number of subjects: 1251
Study 24188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with temporary SCI
Number of subjects: 1251
Study 24188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 1251
Study 24188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery of patients with SCI
Number of subjects: 1251
Study 24188875 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg recombinant hCG (r-hCG)
Number of subjects: 36
Study 24189085 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg liraglutide
Number of subjects: 52
Study 24189085 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide-placebo (control)
Number of subjects: 52
Study 24189578 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Number of subjects: 242
Study 24189578 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy
Number of subjects: 242
Study 24189578 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable gastric banding
Number of subjects: 242
Study 24189578 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall WLS
Number of subjects: 242
Study 24189773 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 2458
Study 24189773 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 2458
Study 24190440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (Roux-en-Y gastric bypass or laparoscopic adjustable gastric banding)
Number of subjects: 106
Study 24190440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 106
Study 24190901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM) parameters including 24-hour systolic blood pressure (SBP), diastolic blood pressure (DBP), percentage of time awake with SBP ≥135 mm Hg, percentage of time asleep with SBP ≥120 mm Hg, and central aortic blood pressure
Number of subjects: 1544
Study 24190901 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis adjusting for age, sex, body mass index, and heart rate
Number of subjects: 1544
Study 24190901 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour blood pressure monitoring
Number of subjects: 1544
Study 24191174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (N = 51)
Number of subjects: 154
Study 24191174 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (N = 51)
Number of subjects: 154
Study 24191174 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (N = 52)
Number of subjects: 154
Study 24192652 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with FH
Number of subjects: 196
Study 24192652 — intervention group
Group type: COMPARATOR
Intervention: Unaffected siblings
Number of subjects: 196
Study 24193798 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-1127 (glyburide for injection) at a dose of 3 mg/d
Number of subjects: 10
Study 24194874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VNS
Number of subjects: 15
Study 24195547 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive index ≥ 0.80
Number of subjects: 321
Study 24195547 — intervention group
Group type: COMPARATOR
Intervention: Biopsies with antibody-mediated rejection or acute tubular necrosis
Number of subjects: 321
Study 24196401 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment during pregnancy
Number of subjects: 883
Study 24196401 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepregnancy obesity
Number of subjects: 883
Study 24196401 — intervention group
Group type: EXPERIMENTAL
Intervention: Older maternal age
Number of subjects: 883
Study 24196401 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal in-hospital breastfeeding
Number of subjects: 883
Study 24196401 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher gestational age (only in multiparous mothers)
Number of subjects: 883
Study 24198310 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI ≥25 kg/m²) in Morocco
Number of subjects: 2500
Study 24198310 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) in Morocco
Number of subjects: 2500
Study 24198310 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI ≥25 kg/m²) in Tunisia
Number of subjects: 2500
Study 24198310 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) in Tunisia
Number of subjects: 2500
Study 24198310 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexistence of overall or central adiposity with ID in Morocco
Number of subjects: 2500
Study 24198310 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexistence of overall or central adiposity with ID in Tunisia
Number of subjects: 2500
Study 24198310 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexistence of overall or central adiposity with anemia in Morocco
Number of subjects: 2500
Study 24198310 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexistence of overall or central adiposity with anemia in Tunisia
Number of subjects: 2500
Study 24198629 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily for 12 weeks
Number of subjects: 923
Study 24198629 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 923
Study 24200517 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated text message based weight loss program (3-5 text messages daily for 8 weeks, including printed materials and weekly counseling calls)
Number of subjects: 20
Study 24200517 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated text message based weight loss program
Number of subjects: 20
Study 24200875 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented modified BESS
Number of subjects: 13
Study 24200875 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented BESS
Number of subjects: 13
Study 24200875 — intervention group
Group type: COMPARATOR
Intervention: Modified BESS
Number of subjects: 13
Study 24200875 — intervention group
Group type: COMPARATOR
Intervention: BESS
Number of subjects: 13
Study 24200998 — intervention group
Group type: EXPERIMENTAL
Intervention: AKN-028
Number of subjects: 0
Study 24201015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with external beam radiation (EB)
Number of subjects: 19
Study 24201857 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose IV sildenafil (0.25, 0.35, or 0.45 mg/kg over 20 min)
Number of subjects: 9
Study 24203067 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs26125 (PPARGC1B)
Number of subjects: 450
Study 24203067 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs4759277 (LRP1)
Number of subjects: 450
Study 24203067 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs184003 (AGER)
Number of subjects: 450
Study 24203067 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs7301876 (ABCC9)
Number of subjects: 450
Study 24203067 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs290481 (TCF7L2)
Number of subjects: 450
Study 24203067 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs12691 (CEBPA)
Number of subjects: 450
Study 24203510 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine coadministration (Days 1 to 11)
Number of subjects: 13
Study 24204746 — intervention group
Group type: EXPERIMENTAL
Intervention: HSVTK-tCD34 suicide gene modified donor T cells
Number of subjects: 3
Study 24205333 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat overfeeding (+1250 kCal/day, 45% fat)
Number of subjects: 40
Study 24205345 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer of care
Number of subjects: 393
Study 24205345 — intervention group
Group type: EXPERIMENTAL
Intervention: Did not transfer care
Number of subjects: 393
Study 24206649 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR screening and species identification assays in a mobile laboratory
Number of subjects: 5000
Study 24206748 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI) video PVCS
Number of subjects: 30
Study 24206748 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging
Number of subjects: 30
Study 24210084 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel
Number of subjects: 385
Study 24210084 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 385
Study 24210146 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ hypothermic perfusion with retrograde outflow during right hemihepatectomy
Number of subjects: 0
Study 24210779 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) with radiofrequency ablation
Number of subjects: 153
Study 24211066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of autologous bone-marrow derived mesenchymal stromal cells (BMMSCs)
Number of subjects: 31
Study 24214373 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg single oral dose
Number of subjects: 20
Study 24214901 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Circulatory Support (MCS)
Number of subjects: 3363
Study 24214905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g intravenously before surgery
Number of subjects: 16
Study 24215775 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care team support model
Number of subjects: 1406
Study 24215775 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-facilitated depression care model
Number of subjects: 1406
Study 24215775 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1406
Study 24218035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (So) treatment
Number of subjects: 45
Study 24218170 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsies from patients with CLI
Number of subjects: 33
Study 24218170 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow biopsies from controls
Number of subjects: 33
Study 24218191 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated preoperative depression
Number of subjects: 107
Study 24218513 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod ointment and subcutaneous vaccinations (100 μg IDO5 peptide, sequence ALLEIASCL, formulated in 900 μL Montanide)
Number of subjects: 15
Study 24219045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (BVR)
Number of subjects: 0
Study 24219412 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical COPD
Number of subjects: 60
Study 24219412 — intervention group
Group type: COMPARATOR
Intervention: Smoking control subjects
Number of subjects: 60
Study 24219412 — intervention group
Group type: COMPARATOR
Intervention: Never-smoking control subjects
Number of subjects: 60
Study 24219412 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical COPD and smoking control subjects
Number of subjects: 60
Study 24219412 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity and smoking
Number of subjects: 60
Study 24220233 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based patient-provider communication service (IPPC)
Number of subjects: 22
Study 24220277 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT intervention with weekly therapist contact
Number of subjects: 150
Study 24220277 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT intervention without therapist contact
Number of subjects: 150
Study 24220277 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 150
Study 24220559 — intervention group
Group type: EXPERIMENTAL
Intervention: R-GCVP (rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 61
Study 24220559 — intervention group
Group type: EXPERIMENTAL
Intervention: R-GCVP
Number of subjects: 61
Study 24220703 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone vaginally daily for 3 months
Number of subjects: 33
Study 24221839 — intervention group
Group type: EXPERIMENTAL
Intervention: Life chaos increase (measured by an instrument)
Number of subjects: 406
Study 24221839 — intervention group
Group type: COMPARATOR
Intervention: CVD-medication nonadherence
Number of subjects: 406
Study 24221839 — intervention group
Group type: EXPERIMENTAL
Intervention: Life chaos factors
Number of subjects: 406
Study 24222348 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 3865
Study 24222348 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 3865
Study 24222348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 3865
Study 24222969 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized fecal microbiota transplantation (FMT)
Number of subjects: 1
Study 24223036 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy
Number of subjects: 205
Study 24223036 — intervention group
Group type: COMPARATOR
Intervention: 12-Step interventions
Number of subjects: 205
Study 24224021 — intervention group
Group type: EXPERIMENTAL
Intervention: ED visit/hospitalization for painful vaso-occlusive crises (VOCs)
Number of subjects: 264
Study 24224021 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tricuspid regurgitatant jet velocity (TRV)
Number of subjects: 264
Study 24224021 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ferritin
Number of subjects: 264
Study 24224021 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower glomerular filtration rate
Number of subjects: 264
Study 24224560 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant viruslike particle influenza A (H7N9) vaccine
Number of subjects: 0
Study 24224624 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Number of subjects: 30
Study 24224624 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-EPOCH-RR
Number of subjects: 30
Study 24224707 — intervention group
Group type: EXPERIMENTAL
Intervention: Low DKK-1 levels
Number of subjects: 0
Study 24224707 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased secreted frizzled related protein-3 levels
Number of subjects: 0
Study 24224707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysregulated Wnt signaling
Number of subjects: 0
Study 24224903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (eight 2-min intervals of 8% oxygen) for 10 days
Number of subjects: 8
Study 24224903 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure to room air
Number of subjects: 8
Study 24225051 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day course of corticosteroid treatment
Number of subjects: 73
Study 24225051 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid treatment
Number of subjects: 73
Study 24225220 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified high flow nasal cannulae (HHHFNC)
Number of subjects: 20
Study 24225220 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 20
Study 24225354 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional and conditional maternal weight standards developed and validated.
Number of subjects: 358
Study 24225354 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional standards
Number of subjects: 358
Study 24225610 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice alert (BPA) tool with stewardship recommendations and access to the navigator
Number of subjects: 1285
Study 24225610 — intervention group
Group type: COMPARATOR
Intervention: Best practice alert (BPA) tool
Number of subjects: 1285
Study 24225725 — intervention group
Group type: EXPERIMENTAL
Intervention: INVOS sensor (a trend monitor using two infrared wavelengths)
Number of subjects: 29
Study 24225725 — intervention group
Group type: EXPERIMENTAL
Intervention: FORE-SIGHT sensor (a monitor using four wavelengths of laser light)
Number of subjects: 29
Study 24225725 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of INVOS and FORE-SIGHT
Number of subjects: 29
Study 24225725 — intervention group
Group type: EXPERIMENTAL
Intervention: Both monitors
Number of subjects: 29
Study 24226257 — intervention group
Group type: EXPERIMENTAL
Intervention: Geneva Risk Score
Number of subjects: 1478
Study 24226257 — intervention group
Group type: EXPERIMENTAL
Intervention: Padua Prediction Score
Number of subjects: 1478
Study 24227820 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenolanib
Number of subjects: 0
Study 24228627 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cervix (<25 mm)
Number of subjects: 87
Study 24228627 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of IL-8 in vaginal secretions
Number of subjects: 87
Study 24228627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of short cervix and IL-8
Number of subjects: 87
Study 24228627 — intervention group
Group type: EXPERIMENTAL
Intervention: Short inflamed cervix (short cervix with IL-8)
Number of subjects: 87
Study 24228627 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sPTB occurrence
Number of subjects: 87
Study 24229439 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous-allergen-specific-immunotherapy (SCIT)
Number of subjects: 248
Study 24232700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabronchial valve treatment
Number of subjects: 10
Study 24232703 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24234516 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 antibody testing in patients with thyroid cancer
Number of subjects: 171
Study 24234516 — intervention group
Group type: COMPARATOR
Intervention: p53 antibody testing in healthy subjects
Number of subjects: 171
Study 24234516 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 antibody testing in dedifferentiated patients with high Tg level and negative radioiodine scan
Number of subjects: 171
Study 24237764 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resting heart rate (HR)
Number of subjects: 522
Study 24237764 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower resting heart rate (HR)
Number of subjects: 522
Study 24237790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivestim™ (filgrastim) as primary or secondary prophylaxis for febrile neutropenia (FN) or as treatment for ongoing FN.
Number of subjects: 2530
Study 24237790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivestim™ therapy
Number of subjects: 2530
Study 24237790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivestim™
Number of subjects: 2530
Study 24239220 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin combined with ABVD
Number of subjects: 51
Study 24239220 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin combined with AVD
Number of subjects: 51
Study 24240617 — intervention group
Group type: EXPERIMENTAL
Intervention: Website providing disease-specific safety information
Number of subjects: 108
Study 24240933 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel LDL-C estimation method (LDL-CN) using an adjustable factor for the TG:VLDL-C ratio
Number of subjects: 1350908
Study 24240933 — intervention group
Group type: COMPARATOR
Intervention: Friedewald LDL-C (LDL-CF)
Number of subjects: 1350908
Study 24240933 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel LDL-C estimation method (LDL-CN)
Number of subjects: 1350908
Study 24240934 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR (Edwards Sapien XT device)
Number of subjects: 7710
Study 24241210 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavopiridol (30 mg/m² bolus, 30 mg/m² continuous infusion to 50 mg/m² bolus, and 50 mg/m² continuous infusion)
Number of subjects: 15
Study 24241533 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20
Study 24242823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhypertensive African American offspring
Number of subjects: 1035
Study 24242861 — intervention group
Group type: EXPERIMENTAL
Intervention: AS1411 (40 mg/kg/day by continuous intravenous infusion on days 1-4 of a 28-day cycle, for two cycles)
Number of subjects: 35
Study 24242861 — intervention group
Group type: EXPERIMENTAL
Intervention: AS1411
Number of subjects: 35
Study 24243422 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin
Number of subjects: 87
Study 24243422 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate analysis for CL/F
Number of subjects: 87
Study 24243422 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate analysis for S0
Number of subjects: 87
Study 24243635 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fasting glucose
Number of subjects: 1247
Study 24243635 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal 2-hour glucose
Number of subjects: 1247
Study 24243787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE) from the pulmonary artery
Number of subjects: 76
Study 24243787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE) from the coronary sinus
Number of subjects: 76
Study 24243787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE)
Number of subjects: 76
Study 24243787 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 76
Study 24244090 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-assisted walking intervention
Number of subjects: 34